Greenphire Expands Flexibility of eClinicalGPS to Increase CRO and Sponsor Control
KING OF PRUSSIA, Pa., June 13, 2018 /PRNewswire/ -- Greenphire, the global leader in financial software for clinical trials, today announced enhancements to its eClinicalGPS site payment solution, expanding configuration and administration options, providing CROs and sponsors unmatched capability, flexibility, and control. With these enhancements, Greenphire is positioned to take an even more collaborative and strategic role with CRO and sponsor partners in identifying the delivery model, whether self-service, full service, or somewhere in between, to maximize the ROI in site payment automation.
Increasing trial complexity and expanding industry emphasis on site centricity are contributing to the rapid evolution of grant payment management. The latest enhancements to Greenphire's SaaS-based eClinicalGPS make it possible for more sponsors and CROs to automate their investigator payment processes globally.
"A one-size-fits-all approach to site payments is not scalable or sustainable in today's clinical research landscape," said Jim Murphy, CEO of Greenphire. "Sponsors and CROs focused on optimizing payment processes need advanced financial features which can be configured to support their unique workflows, as well as those of their investigative sites around the world."
Among the new features and functionality supporting greater sponsor and CRO payment flexibility are:
- Customizable payment execution models, empowering the sponsor or CRO to choose if and where they execute payments
- Funding flexibility, giving sponsors and CROs that use eClinicalGPS the ability to execute payments to fund and pay in any currency
- Dynamic Payment Parsing, enabling sites to simplify payment administration to their contract staff
eClinicalGPS is the site payment software of choice for global sponsors and CROs looking to automate investigator grant payments enterprise-wide. Backed by a team of experts in global financial software development for clinical research that delivers measurable ROI, the SaaS-based solution leads the industry in technology sophistication and adoption around the world.
For more information, or to schedule a demo, contact sales@greenphire.com.
About Greenphire
Greenphire is the global leader in clinical trial payment automation. Greenphire is exclusively focused on optimizing clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. The choice of industry leaders worldwide, Greenphire supports site centricity and sustainability, increases patient engagement and retention, and provides more comprehensive financial data, resulting in better trials. Learn more at www.greenphire.com.
Media Contact:
Kathleen Fusco
(267) 828-4862
Kathleen.Fusco@greenphire.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
